Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O75015: Variant p.Asn65Ser

Low affinity immunoglobulin gamma Fc region receptor III-B
Gene: FCGR3B
Feedback?
Variant information Variant position: help 65 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Asparagine (N) to Serine (S) at position 65 (N65S, p.Asn65Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (N) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism: help There are three allelic forms of FCGR3B: FCGR3B*01 (HNA-1a, NA-1), FCGR3B*02 (HNA-1b, NA-2) and FCGR3B*03 (HNA-1c, SH). FCGR3B*01 and FCGR3B*02 are detectable with antibodies against the biallelic neutrophil-specific antigen system NA. The more active FCGR3B*01 allele has been associated with severe renal disease in certain forms of systemic vasculitides. Additional information on the polymorphism described.
Variant description: help In allele FCGR3B*02 and allele FCGR3B*03. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 65 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 233 The length of the canonical sequence.
Location on the sequence: help LKCQGAYSPEDNSTQWFHNE N LISSQASSYFIDAATVNDSG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         LKCQGAYSPEDNSTQWFHNENLISSQASSYFIDAATVNDSG

Rabbit                        LKCQGLHPAGDNTTQWLHNGSLLSSQAPAYTITAARAEDGG

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 17 – 200 Low affinity immunoglobulin gamma Fc region receptor III-B
Domain 40 – 96 Ig-like C2-type 1
Glycosylation 56 – 56 N-linked (GlcNAc...) asparagine
Glycosylation 63 – 63 N-linked (GlcNAc...) asparagine
Glycosylation 82 – 82 N-linked (GlcNAc...) asparagine
Disulfide bond 47 – 89
Beta strand 65 – 70



Literature citations
A human immunoglobulin G receptor exists in both polypeptide-anchored and phosphatidylinositol-glycan-anchored forms.
Scallon B.J.; Scigliano E.; Freedman V.H.; Miedel M.C.; Pan Y.C.; Unkeless J.C.; Kochan J.P.;
Proc. Natl. Acad. Sci. U.S.A. 86:5079-5083(1989)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT SER-65;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.